drugset / Trial / NCT00255424

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients

NCT00255424

Phase 3 Completed 304 enrolled AMAG Pharmaceuticals, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The study will evaluate the safety and efficacy of a new intravenously administered iron drug to treat anemia in patients with chronic kidney disease who are not on dialysis.

Timeline

Start
2004-05
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent 510 mg Intravenous
Subject Iron Sulfate Small molecule 200 mg Oral

Indications